CytoCore Speeds Trials for e2Collector(TM) to Improve HPV Virus Detection.

New Cervical Cancer Screening Method Offers First Pap Test Advancement in 50 Years

CHICAGO -- Kicking off the new year with an eye toward improving accuracy and efficiency in Pap testing for the deadly Human Papillomavirus (HPV), CytoCore, Inc. (OTCBB:CYCR) today announced a fast-tracked marketing trial to demonstrate their e2 Collector's[TM] superior, more thorough cell sampling technology.

The first major change to the Pap test in 50 years, CytoCore's e2 Collector balloon device reflects the late-stage bio-scientific research company's aggressive commitment to advancing affordable early screening and treatment for uterine, endometrial and cervical cancers that claim the lives of hundreds of thousands of women worldwide every year.

"The e2 is the only procedure that ensures collection of sample cells from the entire cervix," said Dr. Floyd Taub, founder of the company that developed the HPV virus test and a CytoCore Scientific Advisory Board member. "Its patented design automatically collects cells from the endocervix (inside) and ectocervix (outside) in one pain-free step. This simple but elegant device will replace the current weak link in the cervical cancer screening process."

"Since inception the Pap smear test has been limited by the imprecise scraping technique for collecting cells," added Dr. Taub. "Neither the microscopist nor HPV DNA analysis can detect pre-cancerous (dysplasia) nor cancer cells, nor the viruses associated with the cancer, if they are not included in the sample sent to the lab."

Unlike many developments, the benefits of the e2 Collector can be obtained without the need for expensive equipment, reagents, laboratories, 'learning curve' or skilled practitioners. It allows less skilled persons to collect better samples.

"Cytocore's confirmation trial will clearly show the heightened results offered by the e2 Collector balloon collection method versus the traditional spatula-and-brush devices in routine use today," said Dr. George Gorodeski, director of the Medical Advisory Board. "When it comes to taking on cervical cancer-causing HPV, our cell sampling procedure is not only less invasive for the patient and easier for the physician; it also brings an entirely new standard of accuracy to our current Pap testing. Its sensitivity to the presence of virulent HPV strains will also be enormously useful for clinicians in their decision-making process when treating women diagnosed with borderline cervical lesions."

The HPV test is currently being adopted as a standard of care and routine component of any thorough Pap screening. Approximately ten of the 30 identified genital HPV types can lead to development of cervical cancer, according to the Centers for Disease Control website, and the American Cancer Society estimates that nearly 10,000 women were diagnosed in the U.S. this year. Most of those women diagnosed with invasive cervical cancer have not had regular Pap testing. Some 120 million Pap tests are currently administered annually worldwide, including more than 55 million tests performed in the United States alone.

The e2 Collector trial is expected to take 45-60 days and conclude early in 2007. CytoCore is currently ramping up manufacturing and expects to begin production and sales immediately after Federal Drug Administration approval, which is anticipated for the second quarter.

"This trial is expected to provide us with the definitive proof on the Collector's performance advantages," said Dr. Augusto Ocana, CEO of CytoCore. "My focus is on getting the product to market for widespread international adoption with the right distribution partners. Based on initial conversations with my domestic and international connections, I believe we will exceed the Company's previous revenue assumptions for the Collector and believe our market range will be between $150mm-$450 mm worldwide. This device is long overdue, and will be the first major improvement in the experience, performance and accuracy of the Pap test in over 50 years. I believe this cost saving device will be used worldwide."

For further information about the e2Collector and CytoCore's full suite of products for the diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com. For further information about cervical cancer, visit the American Cancer Society's webpage: www.cancer.org.

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.

Dr. George Gorodeski has a significant financial interest in this research consisting of equity and fees from the Company as a consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospital Case Medical Center of Cleveland.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.